Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Taufiq Salahuddin"'
Autor:
Taufiq Salahuddin, MD
Publikováno v:
American Journal of Preventive Cardiology, Vol 19, Iss , Pp 100828- (2024)
Therapeutic Area: Preventive Cardiology Best Practices – clinic operations, team approaches, outcomes research Background: Novel therapies such as angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Externí odkaz:
https://doaj.org/article/7435ab78a6174932b77a7c28802d7caf
Autor:
Taufiq Salahuddin, Annika Hebbe, Marguerite Daus, Carol Simons, Heather Gilmartin, Jacob A Doll
Publikováno v:
Circulation. 147
Background: Novel therapies such as angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose cotransporter-2 Inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have well-established benefit, but use remains low for
Autor:
Taufiq Salahuddin, Annika Hebbe, Christopher P. Kovach, Aaron Strobel, Ehrin J. Armstrong, Stephen W. Waldo
Publikováno v:
Journal of the European Academy of Dermatology and Venereology.
Autor:
Taufiq Salahuddin, Annika L. Hebbe, Marguerite Daus, Carol Simons, Heather M. Gilmartin, Jacob Appel Doll
Publikováno v:
Journal of the American College of Cardiology. 81:1732
Autor:
Donald M. Black, Taufiq Salahuddin, Jean-Claude Tardif, Lawrence A. Leiter, David Kallend, Philip J. Barter, Eran Leitersdorf, Stephen J. Nicholls, Christie M. Ballantyne, Anders G. Olsson, Prediman K. Shah, Gregory G. Schwartz, John Kittelson
Publikováno v:
American Heart Journal. 221:60-66
Background High-density lipoprotein cholesterol (HDL-C) concentration is inversely related to risk of major adverse cardiovascular events (MACE) in epidemiologic studies but is a poorer predictor of MACE in patients with established coronary heart di
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES. 98(3)
Background Little data guides revascularization of infrapopliteal peripheral arterial disease (PAD) in patients with claudication. We assessed outcomes after infrapopliteal-only intervention for claudication in the LIBERTY 360 observational study. Me
Autor:
Jun Liu, Renxia Zhang, Fei Chen, Cuicui Yu, Yan Sun, Chuanliang Jia, Lijing Zhang, Taufiq Salahuddin, Xiaodong Li, Juntian Lang, Xicheng Song
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e75367 (2013)
BACKGROUND: O(6)-methylguanine-DNA methyltransferase is one of the few proteins to directly remove alkylating agents in the human DNA direct reversal repair pathway. A large number of case-control studies have been conducted to explore the associatio
Externí odkaz:
https://doaj.org/article/811cebd6ada34f6c8da3e31cdebdceac
Autor:
Taufiq Salahuddin, David Saxon, P. Michael Ho, Gregory G. Schwartz, Sridharan Raghavan, Kamal Henderson, Javier A. Valle, Demetria M. McNeal, Stephen W. Waldo, Paul L. Hess, Vanessa Richardson
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad7659e8b766e1b8eca7fe3fc71a7af8
https://doi.org/10.1111/dom.14193/v2/response1
https://doi.org/10.1111/dom.14193/v2/response1
Autor:
Vanessa Richardson, Demetria M. McNeal, Gregory G. Schwartz, David Saxon, Paul L. Hess, Sridharan Raghavan, P. Michael Ho, Stephen W. Waldo, Javier A. Valle, Kamal Henderson, Taufiq Salahuddin
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 23(1)
Aim To assess the unrealized potential of glucagon-like peptide-1 receptor agonist (GLP-1RA) or sodium-glucose co-transport-2 inhibitor (SGLT2i) use to reduce mortality in veterans with type 2 diabetes (T2D), coronary artery disease (CAD), and other
Autor:
Sridharan Raghavan, Javier A. Valle, Vanessa Richardson, Paul L. Hess, Taufiq Salahuddin, Michael Ho, Gregory G. Schwartz, David Saxon, Demetria M McNeal, Pamela N. Peterson, Kamal Henderson
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 13
Background: Recent trials have shown improved cardiovascular benefit associated outcomes with sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) treatment in patients (pts) with type 2 diabetes